Here are the latest broker updates from Macquarie. It’s not all pretty for ASX shares.

Macquarie is the latest broker to release its buy and sell tips in early 2022.

| More on:
A surprised and curious male investor drinks black coffee while reading the latest news on rising ASX shares in the newspaper

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The benchmark S&P/ASX 200 Index (ASX: XJO) is trending down today, currently 0.48% in the red at 7,141.4 points at the time of writing.

With the new year well underway, it’s time for the latest round of analyst updates to set the growth outlook for 2022. Macquarie is one of the first with a slew of broker notes coming out of the investment bank’s corner this week.

The broker came out with a list of 8 updates in notes to clients yesterday. Here’s a look at where the team at Macquarie see these ASX shares heading in 2022.

What does Macquarie reckon will outperform?

First off the press is Dexus Industria RIET (ASX: DXI) which analysts from Macquarie upgraded to outperform from neutral in a note today.

The listed fund, under the banner of real estate investment trust (REIT) and property giant Dexus (ASX: DXS), is worth $3.49 per share, according to Macquarie analyst Stuart McLean.

Dexus Industria REIT is trading 1.26% higher at $3.21 at the time of writing, indicating around 9% of upside potential should the broker’s thesis pan out.

The broker also gave Hub24 Ltd (ASX: HUB) an upward revision to outperform from a previous neutral rating. That’s in stark contrast to Macquarie analyst Brendan Carrig’s rating in September 2020 when the stock was tipped to underperform.

Macquarie has now rated Hub24 to outperform and underperform once each. Previously, it had held a neutral rating on two separate occasions. Interestingly, Bloomberg Intelligence reports that “investors who followed Carrig’s recommendation [on Hub24] received a 17% return in the past year, compared with a 3.6% return on the shares”.

Carrig reckons Hub24 is worth $32.40, an 18% upside potential from its current value of $27.44. Carrig’s price is also slightly lower than the consensus figure of $33.29.

Shares in Lendlease Group (ASX: LLC) are also set to outperform in 2022, according to another note from McLean. The analyst upgraded Lendlease from neutral today, assigning a $12.64 price target in the process.

This indicates an upside potential of approximately 21% relative to the current Lendlease share price, which is up 2.36% on the day.

What about the downgrades?

Curiously, the ASX shares the broker has tipped to remain stagnant relative to benchmarks and/or peers were healthcare names.

Macquarie downgraded Estia Health Ltd (ASX: EHE) from outperform to neutral, although its price target on the stock of $2.40 per share still indicates some potential value.

Analyst David Bailey has now rated Estia neutral and outperform once each in the last 18 months. When it was rated neutral, the stock gained 24% on average, whereas it gained 26% when rated as a buy.

At its current value of $2.09, the Estia Health share price has another 14% to climb before reaching Bailey’s price target.

Another downgrade from Bailey was to Integral Diagnostics Ltd (ASX: IDX) which was cut from outperform to neutral in a note today.

Integral is a specialist in providing diagnostic imaging services to medical and allied health professionals. It has a network of 45 sites and operates under a number of brand names.

Bailey had set the price target for Integral Diagnostics at $4.85 — below the consensus of $5.08. This implies there is around 18% upside potential from its price of $4.11 at the time of writing.

Also in the healthcare sector, Bailey has cut Regis Healthcare Ltd (ASX: RRL), Ramsay Healthcare Ltd (ASX: RHC), and Cochlear Ltd (ASX: COH), noting downside risks for each company’s share price in 2022.

Bailey valued Regis at $1.95 per share, Ramsay at $71.85, and Cochlear at $222.50, each below their consensus price targets.

With an aggressive selloff and reshuffling underway within the wider basket of ASX shares, it will be anyone’s guess as to which of these names will outperform the benchmark index this year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. and Hub24 Ltd. The Motley Fool Australia has recommended Cochlear Ltd., Hub24 Ltd, Integral Diagnostics Ltd, and Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Broker Notes

Is now the time to be buying beaten down ASX 200 mining shares?

We take a look at what brokers are saying about ASX mining shares.

Read more »

a man wearing a suit and holding a colourful umbrella over his head purses his lips as though he has just found out some interesting news.
Broker Notes

Here’s why one analyst is ‘cautious’ of the IAG share price

Investors should consider the catastrophe risks, one broker says.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Broker Notes

Could there be another 19% upside to the Aristocrat Leisure share price?

This could be the case, should one broker's thesis play out.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Bell Potter names 2 of the best ASX healthcare shares to buy in FY23

These healthcare shares could be buys for FY 2023...

Read more »

A group of friends watch the game at the pub whilst enjoying a few drinks, one girl has her hand up cheering.
Consumer Staples & Discretionary Shares

Players gonna play: 3 ASX shares set for a strong reporting season

There are some consumer activities that don't just disappear because of an economic downturn. Here are some stocks that could…

Read more »

a young farmer stands back and admires his work in arranging bales of hay to form a house shape with two bales balancing against each other to form a roof, perched on bales tipped on their side in an abstract house shape on a freshly harvested paddock.
Small Cap Shares

2 ASX shares you never heard of ready to make hay

Plummeting stock prices don't necessarily reflect the prospects of many businesses at the moment.

Read more »

a sad looking engineer or miner wearing a high visibility jacket and a hard hat stands alone with his head bowed and hand to his forehead as he speaks on a mobile telephone out front of what appears to be an on site work shed.
Resources Shares

Should investors dig the BHP share price in July?

BHP shares are sinking. Is it time to jump on the ASX mining giant?

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Healthcare Shares

Why this broker is tipping the ResMed share price to rise 17%

A leading broker says ResMed shares can rise strongly from here...

Read more »